Brain and Movement Research Group, Campus for Ageing and Vitality, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle Upon Tyne, UK.
Neurol Sci. 2023 Dec;44(12):4205-4217. doi: 10.1007/s10072-023-07007-0. Epub 2023 Aug 18.
The prevalence of sarcopenia (reduced skeletal muscle strength and mass), Parkinson's disease (PD) and Parkinson's related disorders (PRD) all increase with age. They also share risk factors and pathogenetic features. An increased prevalence of sarcopenia in PD and PRD than the general population was thus postulated.
Four databases were searched using predefined literature search strategies. Studies conducted in participants with PD or PRD reporting the prevalence of sarcopenia and those providing data to compute the prevalence were included. Pre-sarcopenia, probable/possible sarcopenia and confirmed sarcopenia were defined according to the main sarcopenia working groups. Risk of bias was assessed using the AXIS tool.
1978 studies were identified; 97 assessed in full; 14 met inclusion criteria. The median study quality score was 15/20. The range of probable sarcopenia was 23.9 to 66.7%, and it did not change after excluding PRD participants. The prevalence of confirmed sarcopenia in participants with any parkinsonian disorder ranged from 2 to 31.4%. Including just PD participants, the range was 10.9 to 31.4%. In studies with controls, sarcopenia was more prevalent in PD and PRD. There was a positive non-significant trend between severity of motor symptoms and prevalence of sarcopenia or components of sarcopenia. High heterogeneity precluded meta-analysis, therefore there was insufficient evidence to conclude whether sarcopenia is more prevalent in PD or PRD.
Probable and confirmed sarcopenia are common in PD and PRD and they may be associated with disease severity. This co-occurrence supports the value of screening for sarcopenia in parkinsonian populations.
肌肉减少症（骨骼肌力量和质量下降）、帕金森病（PD）和帕金森相关疾病（PRD）的患病率均随年龄增长而增加。它们也具有共同的危险因素和发病特征。因此，有人推测 PD 和 PRD 中的肌肉减少症患病率高于普通人群。
使用预先设定的文献检索策略，在四个数据库中进行检索。纳入报告 PD 或 PRD 患者肌肉减少症患病率并提供计算患病率数据的研究。根据主要肌肉减少症工作组的定义，将前肌肉减少症、可能/可疑肌肉减少症和确诊肌肉减少症进行定义。使用 AXIS 工具评估偏倚风险。
共确定了 1978 项研究，其中 97 项进行了全面评估，14 项符合纳入标准。研究质量评分中位数为 15/20。可能肌肉减少症的范围为 23.9%至 66.7%，排除 PRD 参与者后并未改变。任何帕金森病患者中确诊肌肉减少症的患病率范围为 2%至 31.4%。仅包括 PD 患者时，范围为 10.9%至 31.4%。在有对照组的研究中，PD 和 PRD 患者的肌肉减少症更为普遍。肌肉减少症或其组成部分的患病率与运动症状的严重程度之间呈正相关，但无统计学意义。由于存在高度异质性，因此无法进行荟萃分析，因此没有足够的证据得出肌肉减少症在 PD 或 PRD 中更为普遍的结论。
PD 和 PRD 中常见可能和确诊的肌肉减少症，且可能与疾病严重程度相关。这种同时发生支持在帕金森人群中筛查肌肉减少症的价值。
